Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17470133 | 0.87 | KAT2B (0.36) | KAT2B | |
| SCHEMBL17470172 | 0.86 | MAPKAPK2 (0.32) | — | |
| SCHEMBL17470011 | 0.80 | — | — | |
| SCHEMBL17470136 | 0.77 | MEN1 (0.36) | — | |
| SCHEMBL17470007 | 0.77 | MAPKAPK2 (0.35) | — | |
| SCHEMBL17470051 | 0.75 | PLK1 (0.33) | — | |
| SCHEMBL17470005 | 0.75 | PSEN1 (0.34) | — | |
| SCHEMBL19286227 | 0.73 | KAT2B (0.35) | KAT2BCDK1CDK4CCNB1CCNA2 | |
| SCHEMBL17470194 | 0.73 | CA2 (0.40) | — | |
| SCHEMBL17470008 | 0.73 | MAPKAPK2 (0.34) | KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744528-B2 | Metallorganocatalysis for asymmetric transformations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | Rutgars, The State University of New Jersey (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023198-A1 | Metallorganocatalysis For Asymmetric Transformations | SOD1, AOC3, CBR1 | KAT2B 651/4885CDK1 1634/4885CDK4 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.